High incidence of subclinical peripheral artery disease in people with HIV

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Moises Alberto Suarez-Zdunek
  • Julie Høgh
  • Ditte Marie Kirkegaard-Klitbo
  • Anne Marie R. Jensen
  • Adam Rupert
  • Marius Trøseid
  • Gerstoft, Jan
  • Poulsen, Susanne Dam
  • Andreas D. Knudsen

Objective:Atherosclerosis is common in people with HIV (PWH). Peripheral artery disease (PAD) is the peripheral manifestation of atherosclerosis, but little is known about the incidence of PAD in PWH. Our objective was to determine the PAD incidence in PWH and to investigate potential risk factors.Design:Prospective longitudinal study on PWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study cohort.Methods:We performed ankle-brachial index (ABI) measurements at study entry and at 2-year follow-up and included participants with normal ABI at study entry. We defined de novo PAD as ABI ≤0.9 at follow-up. Using Poisson regression adjusted for age, sex, and smoking, we investigated the role of traditional and HIV-related risk factors, including inflammatory markers.Results:Of 844 PWH followed for a median duration of 2.3 years, 30 (3.6%) developed de novo PAD. All cases were subclinical. Diabetes (relative risk [RR] = 4.90 [95% confidence interval [CI]: 1.99-12.1]), current CD4+ cell count <350 cells/μl (2.66 [1.06-6.71]), longer duration of antiretroviral therapy (antiretroviral therapy [ART], 1.88 [1.06-3.33] per decade), and concentrations of high-sensitivity C-reactive protein (1.33 [1.08-1.63] per doubling) and interleukin-6 (1.38 [1.06-1.80] per doubling), were associated with de novo PAD.Conclusions:PWH had a high incidence of de novo subclinical PAD. Diabetes, low current CD4+ cell count, duration of ART, and inflammatory markers were associated with de novo PAD, indicating a possible role in PAD pathogenesis in PWH.

OriginalsprogEngelsk
TidsskriftAIDS
Vol/bind36
Udgave nummer10
Sider (fra-til)1355-1362
Antal sider8
ISSN0269-9370
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
J.H. received grants from Novo Nordic Foundation and Rigshospitalet Research Council, both unrelated to this manuscript; M.T. reports advisory board activity for Eli Lilly, unrelated to this manuscript; S.D.N. has received unrestricted research grants from Novo Nordisk Foundation, Lundbeck Foundation, Augustinus Foundation, and Rigshospitalet Research Council, and reports advisory board activity for Gilead Sciences and GlaxoSmithKline/ViiV Healthcare, all unrelated to this manuscript; A.D.K. has received a grant from the Danish Heart Foundation. For the remaining authors, no conflicts of interest were declared.

Funding Information:
We sincerely thank the PWH and staff at the Departments of Infectious Diseases at Copenhagen University Hospital – Rigshospitalet and Amager-Hvidovre Hospitals for their dedicated participation. This work was supported by unrestricted research grants from Gilead Sciences, Novo Nordisk Foundation, and Rigshospitalet Research Council.

Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ID: 321966726